Stephen John Ralph (Stephen J Ralph)

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 4

Top Topics

Cognitive Impairment

Cancer Stem Cells

Juvenile Idiopathic Arthritis

Top Venues

Cancer immunology, immunotherapy : CII

Medicinal research reviews

Dementia (London, England)

Expert opinion on investigational drugs

Griffith University Griffith Health

University of Otago Wellington (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Griffith University Griffith Health

Australia

Associate Professor :: School of Medical Sciences

Monash University

Australia

Group Leader :: Biochemistry and Molecular Biology

Ludwig Institute for Cancer Research Parkville Branch

Australia

QE II, National Science Fellow

Salk Institute for Biological Studies

United States

New Zealand Cancer Society Fellow :: Cancer Biology

Education History

University of Otago Wellington

New Zealand

PHD :: Malaghan Institute of Medical Research

University of Auckland

New Zealand

MSC :: Cell Biology

University of Otago

New Zealand

BSC

Publications

Stephen John Ralph, Maxwell J Reynolds
Intratumoral pro-oxidants promote cancer immunotherapy by recruiting and reprogramming neutrophils to eliminate tumors. Cancer immunology, immunotherapy : CII (2022)
Stephen John Ralph, Andrew Weissenberger, Ventzislav Bonev, Liam D King, Mikaela D Bonham, Samantha Ferguson, Ashley D Smith, Adrienne A Goodman-Jones, Anthony J Espinet
Phase I/II parallel double-blind randomized controlled clinical trial of perispinal etanercept for chronic stroke: improved mobility and pain alleviation. Expert opinion on investigational drugs 29 (3) (2020)
Stephen John Ralph, Sam Nozuhur, Reem Ali ALHulais, Sara Rodríguez-Enríquez, Rafael Moreno-Sánchez
Repurposing drugs as pro-oxidant redox modifiers to eliminate cancer stem cells and improve the treatment of advanced stage cancers. Medicinal research reviews 39 (6) (2019)
Stephen John Ralph, Anthony J Espinet
Use of antipsychotics and benzodiazepines for dementia: Time for action? What will be required before global de-prescribing? Dementia (London, England) 18 (6) (2017)